Lyra Therapeutics (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- September 26, 2018
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $29,500,000
Company Info
- Founders
- Maria Palasis
- Company Description
- Lyra Therapeutics is a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, offering an alternative to conventional treatments or surgeries. The company's lead drug candidate, LYR-210, offers a novel approach for directing anti-inflammatory medicine deep into sinonasal tissues for up to six months of therapy.
- Market
- Ear, Nose and Throat (ENT) diseases
- Location
- Watertown, MA, USA
- Coinvestors
- ArrowMark Partners, Perceptive Advisors, RA Capital Management, Soleus Capital